Zepbound for Sleep Apnea: The FDA-Approved Use

Zepbound for sleep apnea is now an FDA-approved treatment, making tirzepatide the first medication ever cleared to treat moderate-to-severe obstructive sleep apnea (OSA) in adults who also have obesity. The approval, granted in December 2024, was built on the SURMOUNT-OSA trial, which showed that tirzepatide cut the number of breathing interruptions during sleep by roughly half while producing substantial weight loss. This matters because it reframes Zepbound as more than a weight medication: for a large group of people, the breathing problem and the weight are the same problem, and treating one treats the other.

What the FDA actually approved

In December 2024 the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, to be used together with a reduced-calorie diet and increased physical activity. It was the first drug the agency had ever approved for OSA, a condition that had been managed for decades almost entirely with devices and surgery rather than medication.

The wording of the indication is precise and worth reading carefully. Zepbound is approved for OSA in adults with obesity. It is not approved for people with sleep apnea who are at a normal weight, and it is not positioned as a universal replacement for continuous positive airway pressure (CPAP). The mechanism is weight-driven, so the approval is tied to the population in whom weight loss is expected to relieve the airway obstruction.

How Zepbound treats sleep apnea

Obstructive sleep apnea happens when the soft tissues of the upper airway collapse and block airflow during sleep, usually repeatedly through the night. Each blockage forces a brief arousal as the body fights to breathe, fragmenting sleep and dropping blood oxygen. In people with obesity, fat deposits around the neck, tongue, and upper airway, along with reduced lung volume from abdominal fat, are major contributors to that collapse.

Tirzepatide does not act on the airway directly. It is a dual GLP-1 and GIP receptor agonist that reduces appetite and food intake, which drives weight loss. As body weight and, importantly, the fat around the airway and abdomen decrease, the mechanical pressure that closes the airway eases. Fewer collapses means fewer apnea events. If you want the underlying pharmacology, our explainer on how tirzepatide works covers the receptor biology in detail. The short version for sleep apnea: this is weight loss translated into easier breathing, not a drug that splints the throat open the way a CPAP machine does.

The SURMOUNT-OSA trial results

The approval rested on SURMOUNT-OSA, published in the New England Journal of Medicine in 2024. The program ran two parallel phase 3 trials in adults with moderate-to-severe OSA and obesity: one in people who were not using CPAP, and one in people who were using it. Participants received either tirzepatide at the maximum tolerated dose (10mg or 15mg weekly) or placebo for 52 weeks.

The primary measure was the apnea-hypopnea index (AHI), the number of times per hour that breathing stops or becomes shallow. AHI is the standard yardstick for grading sleep apnea severity, where 5 to 15 is mild, 15 to 30 is moderate, and above 30 is severe.

The reductions were large. Across the two trials, tirzepatide lowered AHI by roughly 25 to 30 events per hour, compared with only a few events per hour on placebo. In relative terms that was close to a 50% to 60% reduction in breathing interruptions. A meaningful share of participants dropped far enough to be reclassified to mild disease or to meet the threshold for disease resolution. The weight loss that accompanied this was on the order of 18% to 20% of body weight, consistent with what tirzepatide produces in dedicated obesity trials.

Measure	Tirzepatide	Placebo
AHI reduction (events/hour)	~25 to 30 fewer	~5 fewer
Relative AHI change	~50% to 60% lower	Small change
Mean body weight change	~18% to 20% loss	Minimal
Trial length	52 weeks	52 weeks

Beyond the headline AHI numbers, the trials reported improvements in markers that patients actually feel and that clinicians worry about: lower blood pressure, reduced inflammatory markers, and better patient-reported sleep impairment and daytime functioning. These secondary findings are part of why sleep specialists took the result seriously rather than treating it as a weight study with a sleep footnote.

Who qualifies for Zepbound for sleep apnea

The label and the trial population point to a fairly specific group. You are most likely to be a candidate if you have:

• A formal diagnosis of moderate-to-severe obstructive sleep apnea, confirmed by a sleep study (AHI of 15 or higher).
• Obesity, generally defined as a body mass index of 30 or above.
• Adult age (the approval is for adults).
• No contraindications to tirzepatide, such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

The diagnosis step matters. Sleep apnea is confirmed with either an in-lab polysomnogram or a validated home sleep test, not with symptoms alone. Many people who snore and feel tired have never had that study done. If sleep apnea is suspected but undiagnosed, the first move is testing, not a prescription. Our guide to who qualifies for a GLP-1 prescription walks through the broader eligibility picture, and any of these medications requires evaluation by a licensed clinician.

Does Zepbound replace CPAP?

This is the question that gets the approval misread, so it is worth being blunt. Zepbound is not a blanket replacement for CPAP, and the FDA did not approve it as one. CPAP remains the first-line, gold-standard therapy for moderate-to-severe OSA, and it works the night you start it by physically holding the airway open. Zepbound works gradually, over months, by removing the weight that narrows the airway.

SURMOUNT-OSA deliberately studied tirzepatide both with and without CPAP, and the results support a few practical reads:

• Alongside CPAP: For people who tolerate CPAP, adding tirzepatide can reduce the underlying severity of the disease and improve weight, blood pressure, and other metabolic measures. The two approaches are not in competition.
• Instead of CPAP, for some: Many patients cannot tolerate CPAP or refuse to use it consistently. For those people, a drug that reduces AHI is a genuine option where the realistic alternative was no effective treatment at all.
• Possible step-down: If enough weight is lost and a repeat sleep study shows the AHI has fallen substantially, some patients may be able to reduce reliance on devices. That decision belongs to a sleep clinician working from a fresh sleep study, not to the patient alone.

The honest framing is that Zepbound expands the menu of effective OSA treatments rather than knocking the old options off it.

The insurance and coverage angle

One of the most consequential effects of this approval has nothing to do with the airway. GLP-1 medications for weight loss are frequently denied by insurers, who often exclude "weight loss drugs" from coverage outright. An FDA-approved indication for obstructive sleep apnea is a separate, recognized medical condition with its own billing codes.

For a patient who has both obesity and diagnosed moderate-to-severe OSA, a prescription written for the sleep apnea indication can open a coverage path that a weight-loss-only prescription would not. It does not guarantee approval, and plans vary widely, but it changes the conversation with the insurer from a lifestyle request to a treatment for a documented disease with cardiovascular consequences. That distinction can be the difference between paying a copay and paying full retail. For the underlying price reality, see our breakdown of Zepbound cost per month, which matters a great deal if coverage falls through.

Dosing

Dosing for the OSA indication follows the same escalation schedule used for weight management, because it is the same drug at the same strengths. Tirzepatide is a once-weekly subcutaneous injection that starts low and steps up slowly to limit side effects.

Phase	Typical dose	Duration
Starting dose	2.5mg weekly	4 weeks
First step up	5mg weekly	4 weeks
Further titration	7.5mg, 10mg, 12.5mg as needed	4 weeks each
Maintenance (OSA target)	10mg or 15mg weekly	Ongoing

The 2.5mg starting dose is a tolerability step and is not expected to treat the sleep apnea on its own. The therapeutic benefit in SURMOUNT-OSA came at the maximum tolerated dose of 10mg or 15mg, so reaching and maintaining a higher dose is part of the plan, not optional. Zepbound and Mounjaro are the same molecule under different brand names; the differences are in indication and packaging rather than the drug itself, which we cover in Mounjaro vs Zepbound.

Side effects

The side effect profile for sleep apnea patients is the same as for tirzepatide in any other use, because it is the same drug. The dominant issues are gastrointestinal: nausea, diarrhea, constipation, and vomiting, mostly mild to moderate and concentrated during the dose-escalation period. Most people find these ease as the body adjusts and as the dose stabilizes.

Less common but more serious concerns include pancreatitis, gallbladder problems (more likely with rapid weight loss), and the boxed warning about thyroid C-cell tumors based on rodent studies, which is why a personal or family history of medullary thyroid cancer rules the drug out. As with any weight loss this fast, attention to protein intake and resistance exercise helps preserve muscle. The broader trial safety record is summarized in our piece on Zepbound clinical trial results.

How to get evaluated

The path usually runs through two clinicians: a sleep evaluation to confirm and grade the apnea, and a prescriber to assess whether tirzepatide is appropriate and to manage the titration. Some telehealth services can coordinate both the metabolic and the sleep side, and our overview of the best telehealth GLP-1 prescriptions outlines what to look for. Whichever route you take, a documented OSA diagnosis is the anchor for both the clinical decision and any insurance claim.